Memory Pharmaceuticals Reports Phase 1 Data For R4996/MEM 63908

Memory Pharmaceuticals Corp. (Nasdaq: MEMY) announced positive results from its Phase 1 program for R4996/MEM 63908, a partial agonist of the nicotinic alpha-7 receptor being developed in collaboration with Roche for cognitive disorders such as Alzheimer’s disease. The Phase 1 program enrolled over 130 subjects and included a single-ascending dose study, a food interaction study, a study in elderly volunteers and a multiple ascending dose study.

More: continued here

Filed under: Alzheimer's / Dementia News XML/RSS Feed on January 4th, 2009